RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement

mRNA vaccines have amassed a strong interest from scientists and nonscientists alike for their potential in treating cancer and curbing the spread of infectious diseases. Their success has been bolstered by the COVID-19 pandemic as mRNA vaccines for the SARS-CoV-2 virus showed unrivaled efficiency a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hana M. Abdelzaher, Asmaa S. Gabr, Basma M. Saleh, Rana M. Abdel Gawad, Ahmed A. Nour, Anwar Abdelanser
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	mRNA vaccines infectious diseases challenges clinical trials SARS-CoV-2 Medicine R
Acceso en línea:	https://doaj.org/article/fd30f1118b8b40a88168d097a0574fe3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fd30f1118b8b40a88168d097a0574fe3
record_format	dspace
spelling	oai:doaj.org-article:fd30f1118b8b40a88168d097a0574fe32021-11-25T19:10:03ZRNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement10.3390/vaccines91112112076-393Xhttps://doaj.org/article/fd30f1118b8b40a88168d097a0574fe32021-10-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1211https://doaj.org/toc/2076-393XmRNA vaccines have amassed a strong interest from scientists and nonscientists alike for their potential in treating cancer and curbing the spread of infectious diseases. Their success has been bolstered by the COVID-19 pandemic as mRNA vaccines for the SARS-CoV-2 virus showed unrivaled efficiency and success. The strategy relies on the delivery of an RNA transcript that carries the sequence of an antigenic molecule into the body’s cells where the antigen is manufactured. The lack of use of infectious pathogens and the fact that they are made of nucleic acids render these vaccines a favorable alternative to other vaccination modalities. However, mRNA vaccination still suffers from a great deal of hurdles starting from their safety, cellular delivery, uptake and response to their manufacturing, logistics and storage. In this review, we examine the premise of RNA vaccination starting from their conceptualization to their clinical applications. We also thoroughly discuss the advances in the field of RNA vaccination for infectious diseases. Finally, we discuss the challenges impeding their progress and shed light on potential areas of research in the field.Hana M. AbdelzaherAsmaa S. GabrBasma M. SalehRana M. Abdel GawadAhmed A. NourAnwar AbdelanserMDPI AGarticlemRNA vaccinesinfectious diseaseschallengesclinical trialsSARS-CoV-2MedicineRENVaccines, Vol 9, Iss 1211, p 1211 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	mRNA vaccines infectious diseases challenges clinical trials SARS-CoV-2 Medicine R
spellingShingle	mRNA vaccines infectious diseases challenges clinical trials SARS-CoV-2 Medicine R Hana M. Abdelzaher Asmaa S. Gabr Basma M. Saleh Rana M. Abdel Gawad Ahmed A. Nour Anwar Abdelanser RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
description	mRNA vaccines have amassed a strong interest from scientists and nonscientists alike for their potential in treating cancer and curbing the spread of infectious diseases. Their success has been bolstered by the COVID-19 pandemic as mRNA vaccines for the SARS-CoV-2 virus showed unrivaled efficiency and success. The strategy relies on the delivery of an RNA transcript that carries the sequence of an antigenic molecule into the body’s cells where the antigen is manufactured. The lack of use of infectious pathogens and the fact that they are made of nucleic acids render these vaccines a favorable alternative to other vaccination modalities. However, mRNA vaccination still suffers from a great deal of hurdles starting from their safety, cellular delivery, uptake and response to their manufacturing, logistics and storage. In this review, we examine the premise of RNA vaccination starting from their conceptualization to their clinical applications. We also thoroughly discuss the advances in the field of RNA vaccination for infectious diseases. Finally, we discuss the challenges impeding their progress and shed light on potential areas of research in the field.
format	article
author	Hana M. Abdelzaher Asmaa S. Gabr Basma M. Saleh Rana M. Abdel Gawad Ahmed A. Nour Anwar Abdelanser
author_facet	Hana M. Abdelzaher Asmaa S. Gabr Basma M. Saleh Rana M. Abdel Gawad Ahmed A. Nour Anwar Abdelanser
author_sort	Hana M. Abdelzaher
title	RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
title_short	RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
title_full	RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
title_fullStr	RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
title_full_unstemmed	RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
title_sort	rna vaccines against infectious diseases: vital progress with room for improvement
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/fd30f1118b8b40a88168d097a0574fe3
work_keys_str_mv	AT hanamabdelzaher rnavaccinesagainstinfectiousdiseasesvitalprogresswithroomforimprovement AT asmaasgabr rnavaccinesagainstinfectiousdiseasesvitalprogresswithroomforimprovement AT basmamsaleh rnavaccinesagainstinfectiousdiseasesvitalprogresswithroomforimprovement AT ranamabdelgawad rnavaccinesagainstinfectiousdiseasesvitalprogresswithroomforimprovement AT ahmedanour rnavaccinesagainstinfectiousdiseasesvitalprogresswithroomforimprovement AT anwarabdelanser rnavaccinesagainstinfectiousdiseasesvitalprogresswithroomforimprovement
_version_	1718410256634085376

RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement

Ejemplares similares